Risk of damages claims arising from clinical-trial adverse effects and product liability
First written in FY2017. 4 of 5 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2026: 6 of 20 companies on the "Worse" side.
36 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「Conducting clinical trials of pharmaceuticals entails the risk of liability claims arising from adverse effects and other drug-related issues.」
The company continues to disclose liability risks associated with adverse effects in clinical trials and product liability, as well as its response through liability insurance and other measures. - FY2022RestatedAnnual report
「Conducting clinical trials of pharmaceuticals entails the risk of liability claims arising from adverse effects and other drug-related issues.」
The company continues to disclose liability risks associated with adverse effects in clinical trials and product liability, as well as its response through liability insurance and other measures. - FY2021RestatedAnnual report
「Conducting clinical trials of pharmaceuticals entails the risk of liability claims arising from adverse effects and other drug-related issues.」
The company continues to disclose liability risks associated with adverse effects in clinical trials and product liability, as well as its response through liability insurance and other measures. - FY2020RestatedAnnual report
「Conducting clinical trials of pharmaceuticals entails the risk of liability claims arising from adverse effects and other drug-related issues.」
The company continues to disclose liability risks associated with adverse effects in clinical trials and product liability, as well as its response through liability insurance and other measures. - FY2017First statedAnnual report
「Conducting clinical trials of pharmaceuticals entails the risk of liability claims arising from adverse effects and other drug-related issues.」
The company has disclosed the possibility of liability claims arising from adverse effects in clinical trials and inappropriate matters related to development, manufacturing and sales, and is seeking to mitigate the burden through liability insurance and other measures.